Skip to main content

Sequenom, ITI to Develop Newborn Screening Test for SCID

NEW YORK (GenomeWeb News) — Sequenom said today that it has formed a research collaboration with the Immune Tolerance Institute under which ITI will use Sequenom's MassArray system to develop a newborn screening test for severe combined immunodeficiency.

ITI is a non-profit organization formed as a partnership with the University of California, San Francisco. The SCID assay is based on the work of UCSF researcher Jennifer Puck. Sequenom said a recent feasibility study has demonstrated "the adaptability of Dr. Puck’s RT-PCR screening assay for SCID diagnosis on the MassArray platform."

ITI CEO Louis Matis said in a statement that SCID is curable by bone marrow transplants if it is detected in time.

Sequenom CEO Harry Stylii said that the newborn screening test would reflect "the broad applicability" of the MassArray, and he described the collaboration as "in line with our goal of increasing Sequenom's reach in the field of molecular diagnostics."

Financial terms of the deal were not disclosed.

Filed under

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.